Abstract: Endophytes, microorganisms that live in the internal tissues and organs of the plants, are known to produce numerous bioactive compounds, including, at times, some phytochemicals of their host plant. For such reason, endophytes have been quoted as a potential source for discovering bioactive compounds, particularly, of medical interest. Currently, many non-communicable diseases are threatening global human health, noticeably: diabetes, neurodegenerative diseases, cancer, and other ailment related to chronic inflammation and ageing. Intriguingly, the pathogenesis and development of these diseases have been linked to an excessive formation and accumulation of advanced glycation end products (AGEs). AGEs are a heterogeneous group of compounds that can alter the conformation, function, and lifetime of proteins. Therefore, compounds that prevent the formation and consequent accumulation of AGEs (AntiAGEs compounds) could be useful to delay the progress of some chronic diseases, and/or harmful effects of undue AGEs accumulation. Despite the remarkable ability of endophytes to produce bioactive compounds, most of the natural antiAGEs compounds reported in the literature are derived from plants. Accordingly, this work covers 26 plant antiAGEs compounds and some derivatives that have been reported as endophytic metabolites, and discusses the importance, possible advantages, and challenges of using endophytes as a potential source of antiAGEs compounds.

Keywords: diabetes; protein glycation; AGEs detoxification; carboxymethyl-lysine; RAGEs antagonists; methylglyoxal; endophytic metabolites

1. Introduction

Endophytes are microorganisms, mainly fungi and bacteria, that live at least during part of their life cycle within the internal tissues and organs of plants [1]. Endophytes are known to produce several bioactive compounds of pharmaceutical, agricultural, and industrial importance [2,3].

According to the World Health Organization, approximately 56.8% of the annual global deaths come from the most prevalent non-communicable diseases (NCDs): cardiovascular and respiratory diseases, cancer, and diabetes [4]. The high incidence of these diseases has prompted the search for novel alternatives for their prevention and treatment. Interestingly, the pathogenesis and development of several NCDs have been linked to an excessive formation and accumulation of advanced glycation end products (AGEs) [5,6]. AGEs are a heterogeneous group of compounds whose synthesis frequently begins with the non-enzymatic glycation of proteins [7]. The abnormal AGEs accumulation in human body tissues produces deleterious effects involving protein dysfunction, which arises from changes in their conformation (in some cases, AGEs may produce cross-links between
proteins), function, and half-life. Furthermore, AGEs interaction with receptors (RAGEs) can activate inflammatory pathways and lead to the generation of oxidative stress [8].

Consequently, the search for natural compounds that interfere with the AGEs formation and accumulation or that function as AGEs crosslink-breakers or RAGEs antagonists (all of which are referred to as antiAGEs compounds in this review) may lead to the discovery and development of novel therapies for diseases in which AGEs accumulate excessively [9,10].

Most known natural antiAGEs compounds were originally found in plants and encompass various compounds such as polyphenols, polysaccharides, terpenoids, vitamins, alkaloids, and peptides [11–17]. Despite the well-known ability of endophytes to produce bioactive compounds and that sometimes they synthesize the same or similar compounds produced by their host plant [18,19], they have been scarcely studied as producers of antiAGEs compounds.

Thus, our aim was to review and highlight the potential of endophytes as natural sources of antiAGEs compounds. Firstly, we briefly discuss the importance of searching for this kind of compounds due to the suggested connection between excessive AGEs accumulation and development of a large number of chronic diseases. Secondly, we summarize some of the reported antiAGEs plant-derived compounds that have been also found as metabolites of endophytes. Finally, we point out the advantages and challenges of using endophytes instead of plants to discover and produce antiAGEs compounds.

2. Endophytes, an Exceptional Source of Bioactive Compounds

Endophytes comprise mainly fungi and bacteria, but it also includes archaea and protists that live in the internal tissues and organs of plants (leaves, stems, flowers, fruits, seeds, or roots). Some endophytes do not cause apparent signs of disease in their host plants [20]; other may even be beneficial to their host [7], while some could become opportunistic pathogens under particular circumstances [1]. The above depends on the plant and microbial genotype, quorum sensing, co-colonizing microbiota, and environmental conditions [1,21,22]. Endophyte colonization may occur by horizontal transference through different ways, such as soil-to-root, by phyllosphere (aerial spores) or through vectors (pollinators, arthropods, or sap-feeders), and by vertical or mixed transfer via seeds [23]. Endophyte colonization could involve passive or active mechanisms. In the first one, endophytes get access into a plant tissue through cracks, wounds, or hydathodes. On the other hand, active mechanisms involve the secretion of cell-wall-degrading and other enzymes [1,24]. Once inside the plant, the competent endophytes may spread systematically to reach other different plant tissues, mainly via the xylem vascular system [23].

The diversity and composition of endophytic communities in plants depend on biotic factors such as genotype, developmental stage, and physiology of the host plant. Also, microbial strain type, the endophyte chemotaxis to plant-exudates production, and presence of other microorganisms are involved. In addition, abiotic factors such as soil characteristics (pH, moisture, nutrients, presence of pollutants) and environmental conditions (temperature and radiation) could modify the establishment of endophytic communities [1,25,26].

The endophyte–host plant relationship is diverse, complex, and, in many cases, not totally understood. Endophytes could be mutualistic, commensal, and even opportunistic pathogens [1]. In mutualistic endophyte–host plant relationship, the plant offers shelter and nutrients for microorganism survival. In exchange, endophytes can promote plant growth, induce a plant defense response, improve the nutrient’s availability, increase resistance to biotic (salinity, drought, heat, and cold) and abiotic stress (caused by phytopathogens or herbivores), and consequently, enhance the plant survival [26–28].

Some of the interactions mentioned above take place by eliciting host response or by secondary bioactive metabolites produced by the endophytes [1,2,27]. Thus, endophytes synthesize metabolites that may be useful for the host plant, e.g., antifungals, plant-growth promoters, antibiotics, insecticides, antioxidants, and antiparasitic agents. Moreover, several metabolites synthesized by endophytes have shown bioactivities that could be useful
in industrial, agricultural, and medical fields, for example, lytic enzymes, antidiabetics, anti-inflammatory, anticancer, immunosuppressives, antivirals, antiacetylcholinesterase, antimalarial, analgesic, etc. [18,27,29]. Additionally, endophytes at times may be able to produce some of the compounds produced by their host plant [19,29]. In summary, the endophytes represent an interesting and environmentally friendly source of potentially valuable bioactive compounds.

3. Non-Communicable Diseases, a Global Health Problem

For decades, unhealthy diet, sedentary lifestyle, tobacco usage, and alcohol consumption in people around the world have become the main risk factors for the development of non-communicable diseases (NCDs) [4,30]. In 2019, seven of the ten leading causes of death in the world were NCDs or chronic diseases, and it is estimated that their prevalence will continue rising [31]. Accordingly, the detection, treatment, prevention, and palliative care of all these pathologies constitute a crucial challenge for public world health [4]. Moreover, NCDs such as diabetes, cancer, cardiovascular and respiratory diseases are factor risks that have contributed to the severity and rising number of deaths caused by the emergence of the COVID-19 pandemic [32].

Since the pathogenesis and development of some of the main NCDs have been frequently associated with an excessive formation or accumulation of AGEs or the interaction of AGEs with AGEs receptor (RAGE) [33,34], the development of strategies to limit the accumulation of AGEs may be a new potential alternative for the treatment of some NCDs.

4. Advanced Glycation End Products

AGEs are a heterogeneous group of molecules whose formation usually involves non-enzymatic reactions of reducing sugars with proteins through the Maillard reaction [7]. The endogenous formation of AGEs is shown in Figure 1. Initially, the carbonyl group of a reducing sugar reacts with amino groups of proteins, preferentially those of lysine or arginine, to form Schiff bases [35,36]. Rearrangements of the Schiff bases lead to the formation of more stable compounds known as Amadori products (ketoamines) [35,36]. Subsequently, the Amadori products via oxidation, deprotonation, and fragmentation reactions form dicarbonyl compounds in the propagation phase [35]. Methylglyoxal and other α-dicarbonyl compounds are the primary AGEs precursors. These precursors may also originate from sugar autoxidation, lipid peroxidation, amino acid breakdown, and acetone metabolism. Polyol pathway, glycolysis, and fructolysis are metabolic pathways that may contribute to the triose phosphate pool and consequently to the methylglyoxal formation [37–39]. Ultimately, reactions of cyclization, isomerization, retro-aldol cleavage, hydrolytic and oxidative α-cleavage, and β-cleavage may generate a great variety of AGEs in the final phase of AGEs formation [7,38].

Depending on the chemical structure and ability to emit fluorescence, AGEs can be classified as fluorescent and cross-linked, (e.g., pentosidine, crossline, and vespertlysin), fluorescent and non-cross-linked, (e.g., argpyrimidine), non-fluorescent and cross-linked, (e.g., glyoxal-lysine dimer, methylglyoxal-lysine dimer, glyoxal-derived imidazolium cross-link, methylglyoxal-derived imidazolium cross-link, etc.), and non-fluorescent, non-cross-linked adducts, (e.g., carboxymethyl-lysine, carboxyethyl-lysine, pyrraline, and imidazolones) [40]. The cellular formation of AGEs is common under physiological conditions. However, it may undesirably increase under conditions of hyperglycemia, hyperlipidemia, oxidative stress, and inflammation, all of which are common in diabetes, chronic diseases, and ageing [41]. In addition to the endogenous formation of AGEs, exogenous sources such as dietary AGEs (dAGEs) may be consumed from fried or processed foods [42]. Furthermore, AGEs may be inhaled from tobacco smoke, which contributes to the AGEs circulating in the body [43]. Increased rates of AGEs production or accumulation may have pernicious health consequences because AGEs could prompt the formation of covalent cross-links between proteins to form aggregates or may alter the conformation, activity, or function of proteins, as well as their removal by proteolytic means [15,29]. Moreover, AGEs often trig-
ger intracellular signaling processes through their attachment to AGEs receptors (RAGE), so they may cause oxidative stress, inflammatory responses, immune dysfunction, and DNA damage [44,45]. The interactions cited above may explain, at least in part, why AGEs have been linked to a wide range of diseases.

![Diagram of Endogenous AGEs formation in human body](image-url)

**Figure 1.** Endogenous AGEs formation in human body. AGEs are typically formed in three phases. The early phase involves the Maillard reaction between sugar and proteins and concludes with the formation of Amadori products. Subsequently, the propagation phase generates α-dicarbonyl compounds such as methylglyoxal, glyoxal, and 3-deoxyglucosone. A great variety of AGEs emerge during the final phase. In addition, other pathways that could exacerbate the quantity of AGEs precursors comprise sugar autoxidation, aminoacids metabolism, lipids peroxidation, polyol pathway, fructolysis, and glycolysis. Created with BioRender.com. Adapted from Zeng et al. [6].

### 4.1. High Levels of AGEs Accumulation Are Linked to Various Diseases

Diabetic patients recurrently show higher blood sugar concentrations than healthy people, which fosters higher levels of AGEs accumulation and AGEs–RAGEs interactions. This has been linked to the pathogenesis of diabetic complications such as retinopathy, cataract, neuropathy, nephropathy, atherosclerosis, and heart diseases [46–48]. Additionally, increasing AGEs levels contribute to the progression of neurodegenerative diseases, e.g., Alzheimer’s, Parkinson’s, and Huntington’s diseases, and generates cross-links and consequently prompts the formation of the aggregates with amyloid β and tau proteins, α-synuclein, and huntingtin, respectively, as well as alterations via the AGEs–RAGEs axis [49]. Furthermore, AGEs and p53 proteins have been linked to tumorigenesis in lung, breast, colorectal, pancreatic, and melanoma cancer [50].

Other diseases that have been associated with high levels of AGEs or AGEs–RAGEs interactions are cardiovascular diseases [51], sarcopenia [52], osteoporosis [53], inflammatory diseases such as rheumatoid arthritis [54], lupus erythematosus [55], psoriasis [56], chronic lower limb ischemia [57] and chronic obstructive pulmonary disease [58] (Figure 2). Recently, it has been reported that activation of the RAGEs axis could exacerbate clinical complications in COVID-19 patients with diabetes [59].
4.1. High Levels of AGEs Accumulation Are Linked to Various Diseases

Diabetic patients recurrently show higher blood sugar concentrations than healthy people, which fosters higher levels of AGEs accumulation and AGEs–RAGEs interactions. This has been linked to the pathogenesis of diabetic complications such as retinopathy, cataract, neuropathy, nephropathy, atherosclerosis, and heart diseases [46–48]. Additionally, increasing AGEs levels contribute to the progression of neurodegenerative diseases, e.g., Alzheimer’s, Parkinson’s, and Huntington’s diseases, and generates cross-links and consequently prompts the formation of the aggregates with amyloid β and tau proteins, α-synuclein, and huntingtin, respectively, as well as alterations via the AGEs–RAGEs axis [49]. Furthermore, AGEs and p53 proteins have been linked to tumorigenesis in lung, breast, colorectal, pancreatic, and melanoma cancer [50].

Other diseases that have been associated with high levels of AGEs or AGEs–RAGEs interactions are cardiovascular diseases [51], sarcopenia [52], osteoporosis [53], inflammatory diseases such as rheumatoid arthritis [54], lupus erythematosus [55], psoriasis [56], chronic lower limb ischemia [57] and chronic obstructive pulmonary disease [58] (Figure 2). Recently, it has been reported that activation of the RAGEs axis could exacerbate clinical complications in COVID-19 patients with diabetes [59].

4.2. Reducing AGEs Accumulation as a Potential Treatment Strategy for Some NCDs

The high incidence and prevalence of NCDs emphasize the importance of finding new treatment alternatives. It has been proposed that the inhibition of formation or accumulation of AGEs may help to delay or prevent the progression of some non-communicable diseases [10,45,60]. In order to reduce the exogenous AGEs intake, it is often recommended to consume fresh vegetables, fruits, and whole grains, as well as restrict sugary, processed, or fried foods, and cook meals at low temperatures with high humidity. Similarly, having a healthy diet and lifestyle, including exercise and not smoking, are important for the prevention or management of most, if not all, NCDs [61].

Cells possess their own AGEs detoxification systems, e.g., glyoxalase. However, under pathogenic conditions or with ageing, they often become insufficient to keep optimal physiological conditions. Therefore, compounds that inhibit the formation or prevent an excessive accumulation of AGES may represent a potential strategy to retard the onset of detrimental health effects resulting from undue AGEs accumulation and, by doing so, may delay the development of NCDs [10,60].

Due to the rather complex AGEs formation process, several mechanisms exist by which a given compound may operate for this purpose. In this review, we refer to “antiAGEs compounds” as those that may reduce the harmful consequences of AGEs accumulation by at least one of the action mechanisms enlisted below (Figure 3):  

- Blocking the carbonyl groups of reducing sugars or stabilizing the protein structure to inhibit the Maillard reaction or the formation of Schiff bases and Amadori products;
- Scavenging of free radicals and chelating metal ions. Consequently, fewer reactive carbonyl groups and fewer radical-based reactions occur;
- Blocking or breaking the AGEs cross-links to lessen the protein aggregation;
- Disrupting the AGEs–RAGE interaction, thus preventing inflammatory process and oxidative stress;
• Some indirect mechanisms may be stimulating the glyoxalase system and other dicarbonyl detoxification systems to reduce the available AGEs precursors. Inhibition of polyol pathway enzymes (aldose reductase and sorbitol dehydrogenase) to reduce fructose intake and hypoglycemic activity to reduce sugar availability, etc. [9,60].

Figure 3. The mechanisms of action of antiAGEs compounds. The antiAGEs compounds could restrict in different ways, shown with a red cross, the undue accumulation, and consequent harmful effects of AGEs. These compounds may block sugar attachment to proteins, scavenge free radicals, chelate ions, trap reactive dicarbonyl species, break AGEs cross-links, or block the AGEs–RAGEs interaction. Hyperglycemic control and inhibition of aldose reductase or sorbitol dehydrogenase may decrease the reducing sugars available and, therefore, the formation of AGEs. Created with Biorender.com.

4.3. Synthetic AntiAGEs Compounds

Synthetic antiAGEs compounds include aminoguanidine, N-phenacylthiazolium bromide (PTB), tenilsetam, pyridoxamine, pentoxifylline, benfotiamine, LR-90, alagebrum chloride (ALT-711), edaravone, TM2002, pioglitazone and metformin [10]. The two last compounds are widely used for diabetes treatment. Edaravone has been used to treat amyotrophic lateral sclerosis [62], whereas pentoxifylline is used to improve blood flow in patients with circulation problems. However, most of the other antiAGEs compounds have failed in human clinical trials due to severe side effects or deficient effectiveness [10]. For that reason, natural antiAGEs compounds are being studied as a potentially safer and environmentally friendly alternative.

Newman and Cragg [63] wrote: “Natural products still hold out the best options for finding novel agents/active templates, which, when worked on in conjunction with synthetic chemists and biologists, offer the potential to discover novel structures that can lead to effective agents in a variety of human diseases”.

Several natural antiAGEs compounds have been found and identified as plant metabolites, including polyphenols, polysaccharides, terpenoids, vitamins, alkaloids, and peptides [11–17]. In contrast, there are scarce reports about antiAGEs compounds synthesized by endophytes, despite the fact that in some cases, these organisms have the capacity to generate the same or similar bioactive compounds as their host [29,64].

5. Plant AntiAGEs Compounds Also Are Found in Endophytes

Endophytes are a rich source of a wide variety of chemical compounds such as alkaloids, phenols, tannins, amino acids, carbohydrates, saponins, terpenes, flavonoids, and
sterols [65]. Various metabolites and crude extracts of endophytes have shown antioxidant activity, which is known as a possible mechanism for inhibiting the formation of AGEs [66, 67]. Gutiérrez-García et al. [68] explored the anti-AGEs compounds produced by endophytes from Piper auritum. They found that 2,4-diacetylphloroglucinol (DAPG) and congeners such as 5-hydroxyferulic acid synthesized by endophytic Pseudomonas strains inhibit, in vitro, the formation of Amadori products and fluorescent-AGEs.

Natural anti-AGEs compounds have been studied and found primarily in plants. However, some of these plant-derived anti-AGEs compounds have also been found as metabolites synthesized by endophytes [13,29,69,70]. Table 1 summarizes some plant anti-AGEs compounds, their mechanism of action, the endophytes reported to be capable of producing them, and the analytical techniques used to identify these compounds in the endophytes. Table 1 was originally built from the examination of the four most-cited reviews, and three recent reviews, on inhibition of advanced glycation end products by natural products [11–17]. This led us to identify ~130 natural compounds with at least one anti-AGEs activity. Each compound was separately searched in the Web of Science (Core Collection) using the compound name and the phrase “Advanced glycation end products”. Next, the compounds with at least six outputs (62) were searched by name and the input “endophyte”. We retrieved 382 outputs but only 70 were about the production of the anti-AGEs compounds by endophytes, and they included ~30 anti-AGEs compounds. Only the papers that included reliable spectrometric data and chemical information about the compounds synthesized by endophytes were further considered. Table 1 summarizes 26 compounds plus some derivatives, 47 papers about the mechanisms of action involved in the anti-AGEs activity of the compounds cited, and 37 articles reporting endophytes that synthesize at least one of the mentioned compounds.

Table 1. Anti-AGE compounds reported as metabolites synthesized by endophytes.

| Anti-AGEs Compound | Concentration/Study Model | Action Mechanism | Endophytic Source/Host Plant | Analytical Method of Identification |
|--------------------|---------------------------|------------------|------------------------------|-------------------------------------|
| Protocatechuic acid | * 2–4% in powder diet of T2D rats [71] | Reduces formation of CML, pentosidine and the expression of aldose reductase, sorbitol dehydrogenase, and RAGES. Improves glyoxalase I expression and insulin sensitivity. It has antioxidant, hypoglycemic and anti-inflammatory activity [71,72] | -NID endophytes/Neobouldia laevis and Ocimum gratissimum [73] | -HPLC-DAD a -1H, 13C, HSQC, and HMBC NMR a |
| | * 50–100 mg/kg p.o in T2D rats with high fat diet [72] | | -Aspergillus sp., FVL2/Foeniculum vulgare [74] | |
| | | | | |
| Gallic acid | * 50–200 µg/mL in BSA-glucose system [75] | Diminishes fluorescent AGEs formation and RAGEs expression. Chelates ion metals entrap carbonyl species and have antioxidant, anti-inflammatory and hypoglycemic activities [75–77] | -Fusarium sp./Fritillaria unbracteata [78] -Alternaria spp., Penicillium spp., Neurospora spp., Cladosporium spp., Phoma spp. Fusarium spp., Phomopsis spp. and Pleosporales spp./Acer ginnala [79] -Cladosporium velox/Tinospora cordifolia [80] -Fusarium spp./Ferula assa-foetida [81] | -HPLC-DAD b -HPLC-dual λ detector -HPLC-DAD b -HPLC-PDA * |
Table 1. Cont.

| AntiAGEs Compound | Concentration/Study Model | Action Mechanism | Endophytic Source/Host Plant | Analytical Method of Identification |
|-------------------|----------------------------|------------------|-------------------------------|------------------------------------|
| Coumaric acid     | * 0.2 mM in rat hepatocytes [82] * 20 mM in rat tail tendons [83] | Decreases collagen cross-links and cytotoxicity induced by GO and MGO in hepatocytes, has antioxidative and anti-inflammatory activity [82,83] | -Cladosporium velox/Tinospora cordifolia [80] -Fusarium spp./Ferula assa-foetida [81] | -HPLC-DAD b -HPLC-PDA * |
|                   | * 0.5–2 mM in BSA-MGO and histones-MGO system [84] * 2.5–5% in powder diet of T2D rats [85] | Reduces the levels of CML, fluorescent AGEs and inflammatory hormones. Inhibits aldose reductase, sorbitol dehydrogenase activity and RAGEs expression, has antioxidant, anti-inflammatory activities [84–86] * There are contradictory reports about the beneficial effect of caffeic acid. Wu et al. [87] reported proglycation effect of caffeic acid, which leads to the elevation of oxidative stress and inflammation in monocytes, macrophages and vascular endothelial cells * | -Four Fusarium spp./Fritillaria unibracteata [78] -Fusarium chlamydosporum and Penicillium canescens/Polygonum chinense L. [88] -Colletotrichum acutatum S216/Camellia [89] -Aspergillus fumigatus/Moringa oleifera [91] -Cladosporium velox/Tinospora cordifolia [80] -Fusarium spp./Ferula assa-foetida [81] | -HPLC-DAD b -HPLC-ESI-MS/MS b -UPLC-MS/MS b -OHR-LC-MS (ESI and APCI) a |
| Caffeic acid      | * 10 µM in human endothelial cells system [86] * 0.1–2.5 mM BSA-MGO, HUVEC system [87] | Inhibits production of CML, fluorescent AGEs, dicarbonyl compounds, CEL, and melanoidsins. Decreases cytotoxicity induced by GO and MGO in hepatocytes, reduces protein cross-linking and has antioxidant, anti-inflammatory and antihyperglycemic activities [75,82,92–94] | -NID endophytes/Newbouldia laevis and Ocimum gratissimum [73] -Three Fusarium spp./Fritillaria unibracteata [78] -Fusarium chlamydosporum and Penicillium canescens/Polygonum chinense L. [88] -Alternaria tenuissima SBUp1, Fusarium sp./Ferula assa-foetida [81] | -HPLC-PDA a -HPLC-DAD b -HPLC-ESI-MS/MS b -HPLC-PDA * |
| Ferulic acid      | * 50–200 µg/mL in BSA-glucose system [75]. * 0.2 mM in rat hepatocytes [82] * Equimolar or a 5-fold molar excess with respect to the lysine content of flour and egg white in cake [92]. * 12.95 mM in BSA-fructose or soy glycincin–fructose system [93] * 5–20 mM in BSA-glucose system; 0.1 and 0.2 mM in HUVEC system [94] | Inhibits formation of fluorescent AGEs, CML, dicarbonyl compounds, CEL, and melanoidsins. Decreases MGO levels, protein aggregation, and fibril formation induced by AGEs in human serum albumin [95,96] | -NID endophytes/Newbouldia laevis and Ocimum gratissimum [73] -Three Fusarium spp./Fritillaria unibracteata [78] -Fusarium chlamydosporum and Penicillium canescens/Polygonum chinense L. [88] -Alternaria tenuissima SBUp1, Fusarium sp./Ferula assa-foetida [81] | -HPLC-PDA a -HPLC-DAD b -HPLC-ESI-MS/MS b -HPLC-PDA * |
| Rosmarinic acid   | * 6.25–400 µg/mL in BSA-glucose, BSA-GO and BSA-MGO system [95] * 10 µM in HSA–MGO system [96] | Inhibits formation of fluorescent AGEs, CML, and CEL. Reduces MGO levels, protein aggregation, and fibril formation induced by AGEs in human serum albumin [95,96] | -NID endophytes/Newbouldia laevis and Ocimum gratissimum [73] -Three Fusarium spp./Fritillaria unibracteata [78] -Alternaria tenuissima SBUp1, Fusarium sp./Ferula assa-foetida [81] | -HPLC-DAD b -HPLC-DAD b -HPLC-DAD b -HPLC-PDA b |
### Table 1. Cont.

| AntiAGEs Compound | Concentration/Study Model | Action Mechanism | Endophytic Source/Host Plant | Analytical Method of Identification |
|-------------------|---------------------------|------------------|-----------------------------|-------------------------------------|
| Chlorogenic acid  | * 0.5–2 mM in BSA-MGO and histones-MGO system [84]  
* AGEs IC₅₀ = 148.32 ± 3.13 µM in BSA-glucose system; crosslinking IC₅₀ = 0.68 ± 0.10 mM in AGEs-BSA-rat tail tendon collagen system; carbonyl trapping IC₅₀ = 48.26 ± 16.98 mM [97] | Inhibits production of fluorescent AGEs and alpha glycosidases. Reduces cross-linking of AGEs-BSA to collagen, entraps MGO, has anti-hyperglycemic and antioxidant activities [84, 97] | -Sordariomyce sp./Eucommia ulmoides [98]  
-Cochliobolus lunatus/Mirabilis jalapa L. [99]  
-Brevibacillus borstelensis B14, Bacillus amyloliquefaciens B17, Bacillus badus B19, Sphingomonas yebuchiae N21, Enterobacter tabaci N22, and Lodderomyces elongisporus P212 and Colletotrichum acutatum S216/Montha haplocaulx (B14, B17, B19), Ipomoea batatas and Camellia [89]  
-Cladosporium velox/Tinospora cordifolia [80]  
-Fusarium sp./Ferula assa-foetida [81] | -HPLC, UPLC-PDA-QTOF-MS  
-LC-ESI-MS/MS  
-Chromogenic method, TLC b  
-HPLC-UV b  
-UP LC-MS/MS  
-HPLC-DAD b  
-HPLC-PDA * |
| Apigenin (A) and derivatives (V = vitexin and I = isovitexin) | * AGEs IC₅₀ = 85.2–185.2 µM in BSA-glucose-fructose system; aldose reductase IC₅₀ A = 2.47–6.67 µM in RLAR system [100]  
* Aldose reductase IC₅₀ V = 1.47 ± 0.06 µM, IC₅₀ I = 0.49 ± 0.08 µM, IC₅₀ A = 0.97 ± 0.26 µM in RLAR system and IC₅₀ V = 12.07 ± 0.03 µM, IC₅₀ I = 0.13 ± 0.03 µM, IC₅₀ A = 11.65 ± 0.07 µM in HRAR system; AGES IC₅₀ V = 243.54 ± 8.86 µM, IC₅₀ I = 175.66 ± 3.73 µM, IC₅₀ A = 204.14 ± 9.31 µM in BSA-fructose-glucose system [101]  
* 10–25 µM IN AGEs-HUVECs system [102] | Inhibits aldose reductase and acetylcholinesterase activities, as well as the formation of fluorescent AGEs. Entraps MGO and reduces inflammatory cytokines and adhesion molecules, has antioxidant and anti-inflammatory activities [100–102] | -Dichotomopilus funicola/Cajanus cajan L. (pigeon pea) [103]  
-Two Fusarium spp./Fritillaria unibracteata [78]  
-Fusarium solani/Cajanus cajan [104]  
-Chaetomium globosum/Cajanus cajan [105]  
-Arcopilus cupreus/Schlechiera oleosa [90]  
-Alternaria tenuissima SBUp1, Fusarium sp./Ferula assa-foetida [81] | -HPLC-ESI-MS  
-HPLC-DAD b  
-HPLC-UV-Vis *, HPLC-UV b  
-HPLC-ESI-MS b  
-1H, 13C NMR a  
-HPLC-MS/MS a  
-OHR-LC-MS (ESI and APCI) a  
-HPLC-PDA * |
| Kaempferol and derivatives | * 2–4 mg/kg b.w./day in rats; 1–5 μM in YPCN cells [106].  
* Scavenging activity IC₅₀ = 39.5–55.5 µM [107].  
* IC₅₀ = 10 µM in RLAR system [108].  
* 20 mg/kg/day in diabetic rats [109] | Inhibits aldose reductase and entraps dicarbonyl compounds. Reduces AGES levels and hyperglycemia, suppressing AGES–RAGEs axis activation. It has antioxidant and anti-inflammatory activities [106–109] | -Mucor fragilis/Sinopodophyllum hexandrum [110]  
-Penicillium setosum/Withania somnifera [111]  
-Aspergillus fumigatus/Moringa oleifera [91] | -TLC b  
-HPLC-UV b, 1H, 13C NMR a  
-HPLC-UV-Vis-Q-ToF-ESI-MS a  
-UHPLC-DAD b |
| AntiAGEs Compound | Concentration/Study Model | Action Mechanism | Endophytic Source/Host Plant | Analytical Method of Identification |
|------------------|---------------------------|------------------|-----------------------------|----------------------------------|
| Luteolin and derivatives | * AGEs IC\(_{50}\) = 16.5–88.9 \(\mu\)M in BSA-glucose-fructose system; aldose reductase IC\(_{50}\) A = 0.087–0.94 \(\mu\)M in RLAR system [100]. * 100 \(\mu\)g/mL in BSA-glucose-fructose system [112] | Inhibits aldose reductase, and production of pentosidine and other fluorescent AGEs. Reduces protein cross-linking [100,112] | -Nigrospora oryzae / Loranthus micranthus [113] -Fusarium sp. / Fritillaria unibracteata [78] -Alternaria tenuissima SBUp1, Fusarium sp. / Ferula assa-foetida [81] | -HPLC-DAD-ESI-MS a, 1H, 13C, HSQC, and HMBC NMR -HPLC-DAD b -HPLC-PDA * |
| Quercetin and derivatives | * 50–200 \(\mu\)g/mL in BSA-glucose system [75] * 100 \(\mu\)M in BSA-glucose, BSA-ribose and BSA-MGO system [77] * AGEs 50% IC\(_{50}\) = 65 \(\mu\)M, Pentosidine IC\(_{50}\) = 18 \(\mu\)M and 75–300 mM in collagen-glucose system [114] * 0.5–2.5 mM in BSA-MGO and BSA-GO system [115] | Inhibits aldose reductase, and the formation of alpha dicarbonyl compounds, CML, and fluorescent AGEs. Entraps MGO and GO, and reduces cross-linking of proteins and glucose autooxidation, chelates metal ions, has antioxidant activity [75,77,108,114,115] | -Nigrospora oryzae / Loranthus micranthus [113] -Fusarium chlamydosporum and Penicillium canescens / Polygonum chinense L. [88] -Penicillium setosum / Withania somnifera [111] -Arcopilus cupreus / Schleicheria oleosa [90] -Aspergillus fumigatus / Moringa oleifera [91] -Alternaria tenuissima SBUp1, Fusarium sp. / Ferula assa-foetida [81] | -HPLC-DAD-ESI-MS a, 1H, 13C, HSQC, and HMBC NMR -HPLC-ESI-MS/MS -HPLC-UV-Vis-Q-ToF-ESI-MS a -OHR-LC-MS (ESI and APCI) a |
| Catechin | * 50–200 \(\mu\)g/mL in BSA-glucose system [75] * 100 \(\mu\)M in BSA-glucose, BSA-ribose and BSA-MGO system [77] * AGES IC\(_{50}\) = 0.049 ± 0.019 mg/mL in BSA-glucose system, radical scavenging IC\(_{50}\) = 7.927 ± 0.007 and 5 mM for MGO scavenging | Inhibits the formation of fluorescent AGEs. Chelates metal ions, entraps dicarbonyl compounds, and has antioxidant activity [75,77,116] | -Fusarium spp. / Fritillaria unibracteata [78] | -HPLC-DAD b |
| Daidzein | * 1 mM in MGO system [117] | Entraps MGO [117] | -Rahnella aquatilis / Emilia sonchifolia [118] | -ESI-MS a, 1H, 13C NMR a |
| Genistein | * 100 \(\mu\)M in BSA-glucose, BSA-ribose and BSA-MGO system [77] * 1 mM in MGO system [117] | Chelates metal ions, entraps MGO, has antioxidant activity [77,117] | -Rahnella aquatilis / Emilia sonchifolia [118] -Arcopilus cupreus / Schleicheria oleosa [90] | -ESI-MS a, 1H, 13C NMR a -OHR-LC-MS (ESI and APCI) a |
| Icariin | * 20 mg/kg/day in diabetic rats [119] * 10 and 20 mg/kg b.w. in diabetic rats [120] | Reduces blood glucose levels in diabetic rats, has antioxidant, anti-inflammatory and antihyperglycemic activities [119,120] | -Fusarium spp. / Fritillaria unibracteata [78] | -HPLC-DAD b |
| AntiAGEs Compound          | Concentration/Study Model | Action Mechanism                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Endophytic Source/Host Plant                                                                 | Analytical Method of Identification |
|---------------------------|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|----------------------------------|
| Rutin and derivatives     | * 50–100 mg/kg body weight in diabetic rats (review) [121] | Inhibits alpha-glucosidases, alpha-amyloses, aldose reductase, intestinal carbohydrate absorption, and AGEs formation. Increases glucose uptake and insulin secretion. Reduces activity of enzymes involved in gluconeogenesis and has antioxidant and anti-inflammatory activities [121] | -Fusarium spp. / Fritillaria unibracteata [78]  
-Aspergillus fumigatus / Moringa oleifera [91]  
-Alternaria tenuissima SBUp1, Fusarium sp. / Ferula assa-foetida [81] | -HPLC-DAD b  
-UHPLC-DAD b  
-HPLC-PDA * |
| Resveratrol               | * 5 mg/kg b.w. in diabetic rats [122]  
* 50–300 µg/mL in BSA-fructose, BSA-MGO and arginine-MGO system; α-amylase IC₅₀ = 3.62 µg/mL and α-glucosidase IC₅₀ = 17.54 µg/mL [123] | Inhibits aldose reductase, alpha-glucosidase, alpha-amylase, and sorbitol dehydrogenase. Chelates metal ions and entraps dicarbonyls. Improves insulin sensitivity, glyoxalase-I activity, and adiponectin levels. Reduces AGEs levels in diabetic rats, has antioxidant and anti-inflammatory activities [122,123] | -Alternaria spp., Botryosphaeria sp., Penicillium spp., Cephalosporium spp., Aspergillus sp., Geotrichum sp., and Mucor sp. / Vitis vinifera L. cv. Merlot, Vitis quinquangulatris and Polygonum cuspidatum [124]  
-Arcopsis aureus, Penicillium spp., Lasiodiplodia spp., Nigrospora sp., Botryosphaeria spp., Fusarium sp., Xilaria sp., Aspergillus spp. and Alternaria sp. / Vitis vinifera [125–127]  
-Aspergillus niger / Vitis vinifera Cabernet Sauvignon [128] | -HPLC-dual λ *  
-Biochemical assays, TLC b  
-HPLC *  
-Chromogenic method, TLC b  
, UV spectra b  
, LC * |
| Tyrosol                   | * 5–20 mg/kg b.w. in normal and diabetic rats [129]  
* α-glucosidase IC₅₀ = 70.8 µg total phenolic/mL [130] | Inhibits alpha-glucosidase, relieves hyperglycemia, and has antioxidant activity [129,130] | -Rhytismataceae sp. / Picea mariana [131]  
-Papulaspora immersa / Smilanthus sonchifolius [132]  
-Phialocephala fortinii / Rhodiola angusta and R. crentula [133]  
-Pestalotiopsis microspore / Manilkara zapota [134] | -HPLC a, ¹H, ¹³C NMR a  
-Optical rotation, IR, ID, and 2D NMR and MS data a  
-HPLC-UV a  
-UPLC/Q-ToF-MS, and ¹H-NMR b  
-¹H, ¹³C NMR a  
, and FABMS a |
Table 1. Cont.

| AntiAGEs Compound | Concentration/Study Model | Action Mechanism | Endophytic Source/Host Plant | Analytical Method of Identification |
|-------------------|---------------------------|------------------|------------------------------|------------------------------------|
| Ellagic acid      | * Aldose reductase IC$_{50}$ = 0.27 µM in HRAR and IC$_{50}$ = 0.047 µM in RLAR system [108] | Inhibits aldose reductase and sorbitol dehydrogenase activities. Reduces production of CEL, CML, and fluorescent AGEs. Entraps dicarbonyl compounds. Enhances insulin signaling, adiponectin receptors, glucose transporters, and inflammatory mediators. Decreases blood glucose levels and has anti-inflammatory activity [108,135] | Cladosporium velox/Tinospora cordifolia [80] - Aspergillus fumigatus/Moringa oleifera [91] | -HPLC-DAD$^b$ -UHPLC-DAD$^b$ |
| Ginsenosides (Rb, Rd, Rg) | * AGEs IC$_{50}$ = 15–220 µM in BSA-fructose-glucose system [136] | Inhibits production of fructosamine, fluorescent AGEs, and CML. Reduces levels of amyloid cross-B structure, has hypoglycemic activity [136] | Fusarium sp. and Aspergillus sp./Panax notoginseng [137] - Fusarium spp., Aspergillus spp., Verticillium spp., Penicillium spp., Nectria spp., and Plectosphaerella sp./Panax ginseng [138] -Penicillium sp., Dictyochaeta sp. and Canarosporium sp./Aralia elata [139] | -HPLC-UV, HPLC-ESI-MS$^b$ -HPLC-PAD$^b$ -HPLC$^b$ |
| Tanshinones       | * 5 and 20 mg/kg/day in transgenic mice [140] -10 mg/kg/day in diabetic rats [141] | Reduces plasma glucose, AGEs levels, and RAGE expression. Suppress the activation of NF-κB signaling pathway mediated by RAGE, has anti-inflammatory activity [140,141] | Trichoderma atroviride/Salvia miltiorrhiza [142] | -HPLC-HRMS/MS$^b$ |
| Stigmasterol      | * 0.1 mg/mL in BSA-glucose system [143] | Inhibits formation of fluorescent AGEs and protein glycoxidation. Entraps carbonyl intermediates, blocks lysyl residues of BSA, and consequently reduces its binding with glucose. It has antioxidant activity [143] | Cunninghamella sp./Salicornia bigelovii Torr [144] | -ESI-MS, $^1$H-NMR$^a$ |
| Emodin            | * AGEs IC$_{50}$ = 118 µM in BSA-fructose-glucose system, aldose reductase IC$_{50}$ = 15.9 µM in RLAR system [145] | Inhibits aldose reductase activity and formation of fluorescent AGEs and CML. Entraps MGO, has antioxidant activity [145] | Talaromyces spp. Apergillus spp. and Fusarium spp./Artemisia annua L. [146] -Coniochaeta velutina/Tsuga heterophylla [147] -Thielavia subthermophila/Hypericum perforatum [148] | -Metabolomic analysis by LC-HRMS/MS$^{ab}$ -LC-MS-IT-TOF and NMR data$^a$ -HPLC-HRMS$^+$ |
| AntiAGEs Compound | Concentration/Study Model | Action Mechanism | Endophytic Source/Host Plant | Analytical Method of Identification |
|------------------|-------------------------|-----------------|-----------------------------|-----------------------------------|
| * Umbelliferone  | * AGEs IC50 = 2.95 ± 0.02 µM in BSA-fructose-glucose system [149] | Inhibits production of alpha-glycosidase, alpha-amylase, aldose reductase, fluorescent AGEs, and alpha-dicarbonyl compounds. Improves insulin secretion and glucose uptake, has antioxidant and hypoglycemic activities [149,150] | -Cladosporium velox/Tinospora cordifolia [80] | -HPLC-DAD b |
|                  | * 15–240 µg/mL in psoas muscle system, α-amylase IC50 = 8.06 µg/mL | | | |
| Matrine          | * 50–100 mg/kg in transgenic mice, 10–50 µM | Inhibits RAGEs activation, has anti-inflammatory activity [151] | -Aspergillus terreus/Sophora flavescens [152] | -HPLC-PAD b |
| Hypericin        | * 1–10 µM in BSA-MGO system, 0.01–0.5 µM in HUVEC-MGO system [153] | Inhibits production of α-glucosidase and fluorescent AGEs. Protects against MGO-induced apoptosis and oxidative damage [153,154] | -Thielavia subthermophila/Hypericum perforatum [148] | -HPLC-HRMS *, detection of hyp-1 gene |
|                  | * α-glucosidase IC50 = 4.66 ± 0.27 mg/L [154] | | | |

MGO: methylglyoxal; GO: glyoxal; NID: not identified; CML: carboxymethyl lysine; CEL: carboxyethyl lysine; ROS: reactive oxygen species; BSA: bovine serum albumin; HSA: human serum albumin; RLAR: rat lens aldose reductase; HRAR: human recombinant aldose reductase; b.w.: body weight; HUVEC: human umbilical vein endothelial cells; HPLC-PDA: high-performance liquid chromatography coupled to a photodiode array detector; DAD: diode array detector; ESI: electrospray ionization; MS/MS: mass spectrometry in tandem; HRMS: high-resolution mass spectrometry; dual λ: dual wavelength absorbance detector; UPLC: ultra-performance liquid chromatography; 1H and 13C NMR: proton and carbon nuclear magnetic resonance; HSQC: heteronuclear single quantum coherence NMR; HMBC: heteronuclear multiple bond correlation NMR; OHR-LC-MS: orbitrap high-resolution liquid chromatography coupled to mass spectrometry; APCI: atmospheric pressure chemical ionization; TLC: thin layer chromatography; UV: ultraviolet; IR: infrared spectroscopy; QToF-MS: quadrupole time of flight mass spectrometry; FABMS: fast atom bombardment mass spectrometry; IT: ion trap. a Comparing with database or literature. b Comparing with standard data processed under the same conditions. * Quantitative method.

As is shown in Table 1, many antiAGEs compounds synthetized by endophytes have been reported. However, we must be very careful because the identity of a compound should be confirmed, if possible, using complementary methods such as NMR, IR, MS, etc. When working with endophytes, is often difficult to obtain enough quantity of a pure compound or the standard to confidently determine its identity and structure. For this reason, the compound’s identity is often assigned based on databases and literature comparisons. Unfortunately, this is often a complex undertaking due to the varied operation conditions of the analytical instruments, (e.g., experimental vs. those used in databases) or spectra similarities existing among compounds of the same type. For example, paclitaxel could give similar UV spectra, retention times in chromatography, and even m/z signals in mass spectrometry to other different taxanes [155]. For small molecule elucidation using high-resolution mass spectrometry, a levels system approach has been proposed to improve the confidence in identification. In this system, level 1 represents the ideal situation where the proposed structure is confirmed via measurement of a reference standard with MS/MS [156]. The above emphasizes the need for further research to determine the ability of endophytes to synthesize some of the antiAGEs plant-derived compounds covered here.

5.1. Plant-Derived AntiAGEs Polyphenols Reported in Endophytes

Many of the compounds that curtail the generation of AGEs are classified as polyphenols, characterized by having an aromatic ring with one or more hydroxyl substituents.
These natural compounds are often found in plants and include phenolic acids, flavonoids, stilbenes, curcuminoids, and coumarins [13,157,158]. Figure 4 shows some antiAGEs phenolic acids that have been reported to be produced by endophytes such as protocatechuic acid [73,74], gallic acid [78–81], coumaric acid [80,81], caffeic acid [78,80,81,88–91], ferulic acid [73,78,81,88], rosmarinic acid [78,81,98], and chlorogenic acid [80,81,89,99].

![Chemical structures of phenolic acids](image)

**Figure 4.** AntiAGEs phenolic acids reported as metabolites in endophytes.

Flavonoids are polyphenolic compounds well known for their beneficial effects on health, some of them have shown antiAGEs activity [12,157,158]. Flavonoids can be classified into isoflavones, flavones, flavanones, flavonols and anthocyanins. Figure 5 shows some antiAGEs flavonoids reported as metabolites in endophytes consisting of: apigenin and derivatives such as vitexin and isovitexin [78,81,90,103–105], kaempferol and derivatives [91,110,111], luteolin [78,81,113], quercetin and derivatives [81,88,90,91,113], catechin [78], daidzein [118], genistein [90,118], icariin [78] and rutin and derivatives [78,81,91].
Figure 5. AntiAGEs flavonoids reported in endophytes. * Endophytes are also able to produce derivatives of these compounds.

Other antiAGEs phenolic compounds that have been reported in endophytes such as resveratrol, a stilbene [124–128], tyrosol [131–134], ellagic acid [80,91], and 2,4-diacetylphloroglucinol [68] are shown in Figure 6.
5.2. AntiAGEs Terpenoids Reported as Metabolites from Endophytes

Terpenoids and isoprenoids are among the most abundant and structurally diverse group of plant natural products; however, endophytes are becoming an increasingly recognized source of these compounds [159]. Some antiAGEs terpenoids reported in endophytes (Figure 7) comprise ginsenosides (Rb, Rd, Rg) [137–139], tanshinones [142], and stigmasterol [144].

Figure 6. Other antiAGEs phenolic compounds reported in endophytes.

Figure 7. AntiAGEs terpenoids reported in endophytes.
5.3. Other AntiAGEs Compounds Reported in Endophytes

In addition, other antiAGEs compounds of different chemical classes have been reported in endophytes (Figure 8), such as the anthraquinone, emodin [146–148], the hydroxycoumarin, umbelliferone [80], the naphthodianthrone, hypericin [148] and the alkaloid, matrine [152].

![Figure 8](image_url). Other antiAGEs compounds reported in endophytes.

6. Endophytes May Encourage the Production of antiAGEs Compounds by Plants

Endophyte inoculation in plants could change through unique interactions, their own secondary metabolite synthesis, or the metabolites produced by the host plant [160]. In some cases, endophytes may elicit the synthesis of certain plant compounds, such as alkaloids [161] and phenolics [162]. Berberine is an isoquinoline alkaloid with antiAGEs activity [163]. Their synthesis in Coptis teeta was positively linked with the presence of Microbacterium species [164]. Phialocephala fortinii, an endophyte from Rhododendron pseudochrysanthum, prompted an increase of rutin, hyperoside, quercitrin, and catechin in seedlings [162]. Various other endophytes have elicited the production of tanshinones in Salvia miltiorrhiza [165].

Moreover, endophytes may modify the compounds produced by their host, giving rise to compounds with distinctive properties and/or bioactivities [19]. For example, Phomopsis sp., an endophyte recovered from Pinus taeda, biotransformed limonene to produce α-terpineol, carvone, limoneno-1,2-diol, and other limonene derivatives [166]. Paraconiothyriu variabile, an endophyte of Cephalotaxus harringtonia, biotransformed the host-glycosylated apigenin and chrysoeriol flavonoids into their respective aglycones [167]. Epicoccum nigrum, an endophyte of Salix sp., was reported to biotransform the host flavonoids into a new kaempferol O-diglycoside [168]. The above examples highlight potential and interesting uses of endophytes to conceivably produce novel antiAGEs compounds.

7. AntiAGEs Compounds Production: Endophytes vs. Plants

Endophytes may have some advantages compared to plants for producing bioactive compounds, as follows:

- Shorter production time. Microorganisms grow much faster than plants. Consequently, metabolite mass manufacturing with endophytes may be achieved in shorter periods compared to plants.
- Environmentally friendly. Culturing microorganisms does not require the use of large land areas. This averts overharvesting and reduces dependence on plant biodiversity.
- Reliable metabolite production throughout the year. Endophyte-based metabolite production does not depend on seasonal growth, in contrast to plants, nor on weather fluctuations or geographical conditions. Secondary metabolites could be produced at any time of the year with endophytes.
• More economical process. Usually, microbial sources of valued products are cheaper because they can be mass-produced; this may have an impact on the market price of the compounds of interest.
• Fewer purification steps. The chemical complexity of microorganisms is relatively lower than that of plants. A less complex chemical profile of endophytes makes the purification process of metabolites easier and potentially less costly [3,103,169].

8. Challenges for the Future Use of Endophytes as Sources of AntiAGEs Compounds

Despite the possible advantages of endophytes as sources of bioactive compounds (compared to plants), a number of constraints still exist that require diligent consideration to take advantage of endophytes as sources for the discovery and commercial production of antiAGEs compounds. Some constraints may include, for example, (i) numerous endophytes are non-cultivable or become unstable under lab conditions and (ii) low growth yields and a reduction of secondary metabolite production when axenic monocultures are performed [170,171].

Moreover, most studies about bioactive compounds of endophytes have been done under axenic monoculture conditions. However, it is well known that endophytes, in their natural habitat, interact with other organisms, including their host plant and their metabolites, possibly leading to regulation of their own secondary metabolism and cooperating roles for producing bioactive compounds [19]. For that reason, it may be crucial to study the endophytes in systems nearby to their natural habitat because this could disclose the whole potential of endophytes communities to produce bioactive metabolites.

Fortunately, new techniques and technologies, biotechnological platforms, and omic sciences could help to better analyze and understand endophytes and their usually complex interactions with other organisms. In addition, genome mining, genetic engineering, and process optimization (elicitor addition, solid sorbent use, and co-culture fermentation) will allow us to improve the yield and productivity of antiAGEs compounds synthesis by endophytes [19,170,171].

9. Conclusions

Endophytes synthesize a wide variety of metabolites, including some specific of their host plant; as such, they seem to be a promising source of antiAGEs compounds. Additionally, endophytes may be useful to elicit the production of bioactive phytochemicals by plants and induce the production of novel ones. However, some outstanding challenges still limit the discovery and commercial use of these microorganisms as sources of antiAGEs compounds and other bioactive compounds. The use of new technologies in biotechnological platforms and the advancement of omic sciences will help in the understanding of endophytes and their complex interactions with other organisms. This new knowledge will allow endophytes to be harnessed as a safe, sustainable, economical, and profitable option for developing new antiAGEs and other pharmaceutic compounds. The above could be a significant aid for the treatment and control of at least some prevalent non-communicable diseases that threaten global health.

Funding: L.S.R.H. has received scholarships (grant 710433 and 754673) from the National Council of Science and Technology (Conacyt), Mexico. The financial support of Cinvestav-IPN is gratefully acknowledged (the research received no external funding).

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

CML, Nε-carboxymethyl-lysine; GOLA, Nε-[2-[(5-amino-5-carboxypentyl) amino]-2-oxoethyl]-lysine; DOLD, 3-deoxyglucosonederived lysine dimer; DODIC, 3-deoxyglucoson e-derived imidazolium cross-link; 3DG-H1, 3-deoxyglucosone-derived hydroimidazolone 1; CEL, Nε-carboxyethyl-lysine; MOLD, methylglyoxal-derived lysine dimer; MODIC,
methylglyoxal-derived imidazolium cross-link; CEA, Nε-carboxyethyl-arginine; MG-H1, methylglyoxal-derived hydroimidazolone 1; MG-H3, methylglyoxal-derived hydroimidazolone 3; THP, tetrahydropyrimidine; GOLD, glyoxal-derived lysine dimer; GODIC, glyoxal-derived imidazolium cross-link; CMC, carboxymethyl cysteine; CMA, Nε-carboxymethyl-arginine; G-H1, glyoxal-derived hydroimidazolone 1.

References

1. Hardoim, P.R.; Van Overbeek, L.S.; Berg, G.; Pirttilä, A.M.; Compton, S.; Campisano, A.; Döring, M.; Sessitsch, A. The hidden world within plants: Ecological and evolutionary considerations for defining functioning of microbial endophytes. Microbiol. Mol. Biol. Rev. 2015, 79, 293–320. [CrossRef] [PubMed]

2. Strobel, G.; Daisy, B. Bioprospecting for microbial endophytes and their natural products. Microbiol. Mol. Biol. Rev. 2003, 67, 491–502. [CrossRef] [PubMed]

3. Gupta, S.; Chaturvedi, P.; Kulkarni, M.G.; Van Staden, J. A critical review on exploiting the pharmaceutical potential of plant endophytic fungi. Biotechnol. Adv. 2020, 39, 107462. [CrossRef] [PubMed]

4. World Health Organization. Non Communicable Diseases. Available online: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases (accessed on 19 May 2022).

5. Ramasamy, R.; Vannucci, S.J.; Yan, S.S.D.; Herold, K.; Yan, S.F.; Schmidt, A.M. Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15, 168–288. [CrossRef]

6. Zeng, C.; Li, Y.; Ma, J.; Niu, L.; Tay, F.R. Clinical/translational aspects of advanced glycation end products. Trends Endocrinol. Metab. 2019, 30, 959–973. [CrossRef]

7. Singh, R.; Barden, A.; Mori, T.; Beilin, L. Advanced glycation end products: A review. Diabetologia 2001, 44, 129–146. [CrossRef]

8. Ott, C.; Jacobs, K.; Haucke, E.; Navarrete Santos, A.; Grune, T.; Simm, A. Role of Advanced glycation end products in cellular signaling. Redox Biol. 2014, 2, 411–429. [CrossRef]

9. Aldini, G.; Vistoli, G.; Stefek, M.; Chondrogianni, N.; Grune, T.; Sereikait, J.; Sadowska-Bartosz, I.; Bartosz, G. Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products. Free Radic. Res. 2013, 47 (Suppl. 1), 93–137. [CrossRef]

10. Jud, P.; Sourij, H. Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review. Diabetes Res. Clin. Pract. 2019, 148, 54–63. [CrossRef]

11. Chinchansure, A.A.; Korwar, A.M.; Kulkarni, M.J.; Joshi, S.P. Recent Development of plant products with anti-glycation activity: A review. RSC Adv. 2015, 5, 31113–31138. [CrossRef] [PubMed]

12. Sadowska-Bartosz, I.; Bartosz, G. Prevention of Protein glycation by natural compounds. Molecules 2015, 20, 3309–3334. [CrossRef] [PubMed]

13. Khan, M.; Liu, H.; Wang, J.; Sun, B. Inhibitory effect of phenolic compounds and plant extracts on the formation of advanced glycation end products: A comprehensive review. Food Res. Int. 2020, 130, 108933. [CrossRef] [PubMed]

14. Parveen, A.; Sultana, R.; Lee, S.M.; Kim, T.H.; Kim, S.Y. Phytochemicals against anti-diabetic complications: Targeting the advanced glycation end product signaling pathway. Arch. Pharm. Res. 2021, 44, 378–401. [CrossRef]

15. Song, Q.; Liu, J.; Dong, L.; Wang, X.; Zhang, X. Novel advances in inhibiting advanced glycation end product formation using natural compounds. Biomed. Pharmacother. 2021, 140, 111750. [CrossRef]

16. Peng, X.; Ma, J.; Chen, F.; Wang, M. Naturally occurring inhibitors against the formation of advanced glycation end products. Food Funct. 2011, 2, 289. [CrossRef] [PubMed]

17. Velichkova, S.; Foubert, K.; Pieters, L. Natural products as a source of inspiration for novel inhibitors of advanced glycation end products (AGEs) formation. Planta Med. 2021, 87, 780–801. [CrossRef]

18. Aly, A.H.; Debbab, A.; Kjer, J.; Proksch, P. Fungal endophytes from higher plants: A prolific source of phytochemicals and other bioactive natural products. Fungal Divers. 2010, 41, 1–16. [CrossRef]

19. Mishra, S.; Sahu, P.K.; Agarwal, V.; Singh, N. Exploiting endophytic microbes as micro-factories for plant secondary metabolite production. Appl. Microbiol. Biotechnol. 2021, 105, 6579–6596. [CrossRef]

20. Stone, J.K.; Bacon, C.W.; White, J.F. An overview of endophytic microbes: Endophytism defined. In Microbial Endophytes; Marcel Dekker: New York, NY, USA, 2000; pp. 29–33.

21. Kloepper, J.W.; McInroy, J.A.; Liu, K.; Hu, C.-H. Symptoms of fern distortion syndrome resulting from inoculation with opportunistic endophytic fluorescent Pseudomonas spp. PLoS ONE 2013, 8, e58331. [CrossRef]

22. Hsieh, C.-W.; Chuang, Y.-Y.; Lee, M.-Z.; Kirschner, R. First inventory of fungi in symptomless and symptomatic Chinese mesona production. Arch. Pharm. Res. 2014, 37, 411–429. [CrossRef]

23. Frank, A.; Saldierna Guzmán, J.; Shay, J. Transmission of bacterial endophytes. Microorganisms 2017, 5, 70. [CrossRef] [PubMed]

24. Compton, S.; Clément, C.; Sessitsch, A. Plant growth-promoting bacteria in the rhizo- and endosphere of plants: Their role, colonization, mechanisms involved and prospects for utilization. Soil Biol. Biochem. 2010, 42, 669–678. [CrossRef]

25. Papik, J.; Folkmanova, M.; Polivykova-Majorova, M.; Suman, J.; Uhlik, O. The invisible life inside plants: Deciphering the riddles of endophytic bacterial diversity. Biotechnol. Adv. 2020, 44, 107614. [CrossRef] [PubMed]
26. Verma, S.K.; Sahu, P.K.; Kumar, K.; Pal, G.; Gond, S.K.; Kharwar, R.N.; White, J.F. Endophyte roles in nutrient acquisition, root system architecture development and oxidative stress tolerance. *J. Appl. Microbiol.* 2021, 131, 2161–2177. [CrossRef]
27. Tan, R.X.; Zou, W.X. Endophytes: A rich source of functional metabolites (1987 to 2000). *Nat. Prod. Rep.* 2001, 18, 448–459. [CrossRef]
28. Khare, E.; Mishra, J.; Arora, N.K. Multifaceted interactions between endophytes and plant: Developments and prospects. *Front. Microbiol.* 2018, 9, 2732. [CrossRef]
29. Singh, A.; Singh, D.K.; Kharwar, R.N.; White, J.F.; Gond, S.K. Fungal endophytes as efficient sources of plant-derived bioactive compounds and their prospective applications in natural product drug discovery: Insights, avenues, and challenges. *Microorganisms* 2021, 9, 197. [CrossRef]
30. World Health Organization; FAO (Eds.) *Diet, Nutrition, and the Prevention of Chronic Diseases: Report of a WHO-FAO Expert Consultation*; WHO Technical Report Series; World Health Organization: Geneva, Switzerland, 2003.
31. World Health Organization. The Top 10 Causes of Death. Available online: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed on 19 July 2021).
32. Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Providers. Available online: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (accessed on 19 January 2022).
33. Reynaert, N.L.; Gopal, P.; Wouters, E.F.M.; Schalkwijk, C.G. Advanced glycation end products and their receptor in age related, non-communicable chronic inflammatory diseases; overview of clinical evidence and potential contributions to disease. *Int. J. Biochem. Cell Biol.* 2016, 81, 403–418. [CrossRef]
34. Kuzan, A. Toxicity of advanced glycation end products (review). *Biomed. Rep.* 2021, 14, 46. [CrossRef]
35. Thornalley, P.J.; Langbort, A.; Minhas, H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. *Biochem. J.* 1999, 344, 109–116. [CrossRef]
36. Ahmed, N. Advanced glycation end products—role in pathology of diabetic complications. *Diabetes Res. Clin. Pract.* 2005, 67, 3–21. [CrossRef] [PubMed]
37. Kalapos, M.P. Methylglyoxal and glucose metabolism: A historical perspective and future avenues for research. *Drug Metabol. Drug Interact.* 2008, 23, 69–92. [CrossRef] [PubMed]
38. Henning, C.; Glomb, M.A. Pathways of the Maillard reaction under physiological conditions. *Glycoconj. J.* 2016, 33, 499–512. [CrossRef] [PubMed]
39. Schalkwijk, C.G.; Stehouwer, C.D.A. Methylglyoxal, a highly reactive dicarbonyl compound, in diabetes, its vascular complications, and other age-related diseases. *Physiol. Rev.* 2020, 100, 407–461. [CrossRef]
40. Perrone, A.; Giovino, A.; Benny, J.; Martinelli, F. Advanced glycation end products (AGEs): Biochemistry, signaling, analytical methods, and epigenetic effects. *Oxid. Med. Cell. Longev.* 2020, 1–18. [CrossRef]
41. Sourris, K.C.; Watson, A.; Jandeleit-Dahm, K. Inhibitors of advanced glycation end product (AGE) formation and accumulation. In *Reactive Oxygen Species*; Schmidt, H.H.H.W., Ghezzi, P., Cuadrado, A., Eds.; Handbook of Experimental Pharmacology; Springer International Publishing: Cham, Switzerland, 2020; Volume 264, pp. 395–423. [CrossRef]
42. Uribarri, J.; Woodruff, S.; Goodman, S.; Cai, W.; Chen, X.; Pyzik, R.; Yong, A.; Striker, G.E.; Vlassara, H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. *J. Am. Diet. Assoc.* 2010, 110, 911–916.e12. [CrossRef]
43. Cerami, C.; Founds, H.; Nicholl, I.; Mitsushashi, T.; Giordano, D.; Vanpatten, S.; Lee, A.; Al-Abed, Y.; Vlassara, H.; Bucala, R.; et al. Tobacco smoke is a source of toxic reactive glycation products. *Proc. Natl. Acad. Sci. USA* 1997, 94, 13915–13920. [CrossRef]
44. Brownlee, M. Negative consequences of glycation. *Metabolism* 2000, 49, 9–13. [CrossRef]
45. Shen, C.-Y.; Lu, C.-H.; Wu, C.-H.; Li, K.-J.; Kuo, Y.-M.; Hsieh, S.-C.; Yu, C.-L. The development of Maillard reaction, and advanced glycation end product (AGE)-Receptor for AGE (RAGE) signaling inhibitors as novel therapeutic strategies for patients with AGE-related diseases. *Molecules* 2020, 25, 5591. [CrossRef]
46. Geh, S.-Y.; Cooper, M.E. The role of advanced glycation end products in progression and complications of diabetes. *J. Clin. Endocrinol. Metab.* 2008, 93, 1143–1152. [CrossRef]
47. Singh, V.P.; Bali, A.; Singh, N.; Jaggi, A.S. Advanced glycation end products and diabetic complications. *Korean J. Physiol. Pharmacol.* 2014, 18, 1. [CrossRef] [PubMed]
48. Groener, J.B.; Oikonomou, D.; Cheko, R.; Kender, Z.; Zemva, J.; Kühm, L.; Muckenthaler, M.; Peters, V.; Fleming, T.; Kopf, S.; et al. Methylglyoxal and advanced glycation end products in patients with diabetes—What we know so far and the missing links. *Exp. Clin. Endocrinol. Diabetes* 2019, 127, 497–504. [CrossRef] [PubMed]
49. Li, J.; Liu, D.; Sun, L.; Lu, Y.; Zhang, Z. Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective. *J. Neurol. Sci.* 2012, 317, 1–5. [CrossRef] [PubMed]
50. Haque, E.; Kamil, M.; Hasan, A.; Irfan, S.; Sheikh, S.; Khatoon, A.; Nazir, A.; Mir, S.S. Advanced glycation end products (AGEs), protein aggreagation and their cross talk: New insight in tumorgenesis. *Glycobiology* 2020, 30, 2–18. [CrossRef]
51. Fukami, K.; Yamagishi, S.; Okuda, S. Role of AGES-RAGE system in cardiovascular disease. *Curr. Pharm. Des.* 2014, 20, 2395–2402. [CrossRef]
52. Dazio, E.; Vettorretti, S.; Lungarella, G.; Messa, P.; Corsi Romanelli, M.M. Sarcopenia in chronic kidney disease: Focus on advanced glycation end products as mediators and markers of oxidative stress. *Biomedicines* 2021, 9, 405. [CrossRef]
53. Willett, T.L.; Pasquale, J.; Grynpas, M.D. Collagen modifications in postmenopausal osteoporosis: Advanced glycation end products may affect bone volume, structure and quality. *Curr. Osteoporos. Rep.* **2014**, *12*, 329–337. [CrossRef]

54. Tarannum, A.; Zarina, A.R.I.F.; Khursheed, A.L.A.M.; Ahmad, S.; Uddin, M. Nitroxidized-albumin advanced glycation end product and rheumatoid arthritis. *Arch. Rheumatol.* **2019**, *34*, 461–475. [CrossRef]

55. Prasad, K.; Bhanumathy, K.K. AGE-RAGE axis in the pathophysiology of chronic lower limb ischemia and a novel strategy for its treatment. *Int. J. Angiol.* **2020**, *29*, 156–167. [CrossRef] [PubMed]

56. Shin, S.; Lee, J.; Yun, H.; Yoon, J.; Kim, Y.; Kim, J.; Lim, Y.; Kang, S.; Kim, Y.; Bang, S.; et al. Advanced glycation end-products in patients with systemic lupus erythematosus. *Rheumatology* **2007**, *46*, 1551–1556. [CrossRef]

57. Papagrigoraki, A.; Maureli, M.; del Giglio, M.; Gisondi, P.; Girolomoni, G. Advanced glycation end products in the pathogenesis of psoriasis. *Int. J. Mol. Sci.* **2017**, *18*, 2471. [CrossRef]

58. Sharma, A.; Kaur, S.; Sarkar, M.; Sarin, B.C.; Changotra, H. The AGE-RAGE axis and RAGE genetics in chronic obstructive pulmonary disease. *Clin. Rev. Allergy Immunol.* **2021**, *60*, 244–258. [CrossRef] [PubMed]

59. Jahan, H.; Choudhary, I. Glycation, carbonyl stress and AGEs inhibitors: A patent review. *Expert Opin. Ther. Pat.* **2015**, *25*, 1267–1284.

60. Liu, Z.; Liu, L.; Lu, H.; Li, H.; Yang, D.; Shu, G.; Zhang, W.; Yang, Y.; Wang, J.; Zhou, Z.; et al. Gallic acid inhibits advanced glycation end products and improves cardiovascular function in diabetic rats. *Sci. Rep.* **2015**, **5**, 11404. [CrossRef] [PubMed]

61. Pati, S.; Diamanti-Kandarakis, E.; Palioura, E. Current perspectives on the health risks associated with the consumption of advanced glycation end products: Recommendations for dietary management. *Diabetes Metab. Syndr. Obes. Targets Ther.* **2015**, *8*, 415. [CrossRef]

62. FDA. FDA Approves Oral Form for the Treatment of Adults with Amyotrophic Lateral Sclerosis (ALS). 2022. Available online: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-oral-form-treatment-adults-amyotrophic-lateral-sclerosis-als (accessed on 29 May 2022).

63. Shin, D.J.; Cragg, G.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *Molecules* **2019**, *24*, 403. [CrossRef]

64. Zhao, J.; Shan, T.; Mou, Y.; Zhou, L. Plant-derived bioactive compounds produced by endophytic fungi. *Mini-Rev. Med. Chem.* **2011**, *11*, 159–168. [CrossRef]

65. Gouda, S.; Das, G.; Sen, S.K.; Shin, H.-S.; Patra, J.K. Endophytes: A treasure house of bioactive compounds of medicinal importance. *Front. Microbiol.* **2016**, *7*, 1538. [CrossRef]

66. Toghiue, R.M.; Boyom, F.F. Endophytes from ethno-pharmacological plants: Sources of novel antioxidants- a systematic review. *Biocatal. Agric. Biotechnol.* **2019**, *22*, 10140. [CrossRef]

67. Crisci, L.; Lauro, M.R.; Puglisi, G.; Panico, A. Natural antioxidant polyphenols on inflammation management: Anti-glycation activity vs. metallloproteinases inhibition. *Crit. Rev. Food Sci. Nutr.* **2018**, *58*, 893–904. [CrossRef]

68. Gutiérrez-Garcia, K.; Neira-González, A.; Pérez-Gutiérrez, R.M.; Granados-Ramirez, G.; Zarraga, R.; Wrobel, K.; Barona-Gómez, F.; Flores-Cotera, L.B. Phylogenomics of 2,4-diacetylphloroglucinol-producing *Pseudomonas* and novel antiglycation endophytes from *Piper auritum*. *J. Nat. Prod.* **2017**, *80*, 1955–1963. [CrossRef] [PubMed]

69. West, B.J.; Deng, S.; Uwaya, A.; Isami, F.; Abe, Y.; Yamagishi, S.; Jensen, C.J. Iridoids are natural glycation inhibitors. *Glycoconj. J.* **2016**, *33*, 671–681. [CrossRef] [PubMed]

70. Vijaykrishnaraj, M.; Wang, K. Dietary natural products as a potential inhibitor towards advanced glycation end products and hyperglycemic pathways: A phytotherapy approach. *Biomed. Pharmacother.* **2021**, *144*, 112336. [CrossRef]

71. Lin, C.-Y.; Tsai, S.-J.; Huang, C.-S.; Yin, M.-C. Antiglycative effects of protocatechuic acid in the kidneys of diabetic mice. *Arch. Rheumatol.* **2011**, *51*, 511–512. [CrossRef]

72. Bhattacharjee, N.; Dua, T.K.; Krhan, R.; Joardar, S.; Nandy, A.; Saha, A.; De Feo, V.; Dewanjee, S. Protocatechuic acid, a phenolic compound on the glycation process of protein. *Food Chem.* **2009**, *113*, 78–84. [CrossRef]

73. Umadevi, S.; Gopi, V.; Elangovan, V. Regulatory mechanism of gallic acid against advanced glycation end products induced cardiac remodeling in experimental rats. *Chem. Biol. Interact.* **2014**, *208*, 28–36. [CrossRef]

74. Bhuiyan, M.N.I.; Mitsuhashi, S.; Sigtomi, K.; Uebukata, M. Quercetin inhibits advanced glycation end product formation via chelating metal ions, trapping methylglyoxal, and trapping reactive oxygen species. *Biosci. Biotechnol. Biochem.* **2017**, *81*, 882–890. [CrossRef]

75. Pan, F.; Su, T.-J.; Cai, S.-M.; Wu, W. Fungal endophyte-derived *Fritillaria unibracteata* var. Wabuensis: Diversity, antioxidant capacities in vitro and relations to phenolic, flavonoid or saponin compounds. *Sci. Rep.* **2017**, *7*, 42008. [CrossRef] [PubMed]
79. Qi, F.-H.; Jing, T.-Z.; Wang, Z.-X.; Zhan, Y.-G. Fungal endophytes from *Acer ginnala* Maxim: Isolation, identification and their yield of gallic acid. *Lett. Appl. Microbiol.* 2009, 49, 98–104. [CrossRef] [PubMed]

80. Singh, B.; Sharma, P.; Kumar, A.; Chadha, P.; Kaur, R.; Kaur, A. Antioxidant and in vivo genoprotective effects of phenolic compounds identified from an endophytic *Cladosporium velox* and their relationship with its host plant *Tinospora Cordifolia*. *J. Ethnopharmacol.* 2016, 194, 450–456. [CrossRef] [PubMed]

81. Parvandi, M.; Rezadoost, H.; Farzaneh, M. Introducing *Alternaria tenuissima* SBUp1, as an endophytic fungus of *Ferula assa-foetida* from Iran, which is a rich source of rosmarinic acid. *Lett. Appl. Microbiol.* 2021, 73, 569–578. [CrossRef]

82. Maruf, A.A.; Lip, H.; Wong, H.; O’Brien, P. Protective effects of ferulic acid and related polyphenols against glyoxal- or methylglyoxal-induced cytotoxicity and oxidative stress in isolated rat hepatocytes. *Chem. Biol. Interact.* 2015, 234, 96–104. [CrossRef]

83. Selvakumar, G.; Venu, D.; Kuttalam, I.; Lonchin, S. Inhibition of advanced glycation end product formation in rat tail tendons by polydatin and p-coumaric acid: An in vitro study. *Appl. Biochem. Biotechnol.* 2022, 194, 399–353. [CrossRef]

84. Gugliucci, A.; Bastos, D.H.M.; Schulze, J.; Souza, M.F.F. Caffeic and chlorogenic acids in *Ilex Paraguariensis* extracts are the main inhibitors of age generation by methylglyoxal in model proteins. *Fitoterapia* 2009, 80, 339–344. [CrossRef]

85. Chao, C.; Mong, M.; Chan, K.; Yin, M. Anti-glycative and anti-inflammatory effects of caffeic acid and ellagic acid in kidney of diabetic mice. *Mol. Nutr. Food Res.* 2010, 54, 388–395. [CrossRef]

86. Toma, L.; Sanda, G.M.; Niculescu, L.S.; Deleanu, M.; Stancu, C.S.; Sima, A.V. Caffeic acid attenuates the inflammatory stress induced by glycolated LDL in human endothelial cells by mechanisms involving inhibition of AGE-receptor, oxidative, and endoplasmic reticulum stress: Caffeic Acid Attenuates Inflammation in Endothelial Cells. *BioFactors* 2017, 43, 685–697. [CrossRef]

87. Wu, C.-H.; Huang, H.-W.; Lin, J.-A.; Huang, S.-M.; Yen, G.-C. The proglycation effect of caffeic acid leads to the elevation of oxidative stress and inflammation in monocytes, macrophages and vascular endothelial cells. *J. Nutr. Biochem.* 2011, 22, 585–594. [CrossRef]

88. Das, M.; Prakash, H.S.; Nalini, M.S. Bioactive sesquiterpene, plasticizer, and phenols from the fungal endophytes of *Polygonum chinense* L. *Ann. Microbiol.* 2018, 68, 595–609. [CrossRef]

89. Wang, X.; Qin, L.; Zhou, J.; Li, Y.; Fan, X. A novel design to screen chlorogenic acid-producing microbial strains from the environment. *Sci. Rep.* 2018, 8, 14756. [CrossRef]

90. Gagana, S.L.; Kumaraswamy, B.E.; Shivanna, M.B. Diversity, antibacterial and antioxidant activities of the fungal endophytes associated with *Schleicheria olosa* (Lour.) Merr. *M. Afr. J. Bot.* 2020, 134, 369–381. [CrossRef]

91. Kaur, N.; Arora, D.S.; Kaia, N.; Kaur, M. Antibiofilm, antiproliferative, antioxidant and antimutagenic activities of an endophytic fungus *Aspergillus fumigatus* from *Moringa oleifera*. *Mol. Biol. Rep.* 2020, 47, 2901–2911. [CrossRef] [PubMed]

92. Srey, C.; Hull, G.L.J.; Connolly, L.; Elliott, C.T.; del Castillo, M.D.; Ames, J.M. Effect of inhibitor compounds on N²-(carboxymethyl)lysine (CML) and N²-(carboxyethyl)lysine (CEL) formation in model foods. *J. Agric. Food Chem.* 2010, 58, 12036–12041. [CrossRef]

93. Silván, J.M.; Assar, S.H.; Srey, C.; Dolores del Castillo, M.; Ames, J.M. Control of the Maillard reaction by ferulic acid. *Food Chem.* 2011, 128, 208–213. [CrossRef]

94. Liu, J.; He, Y.; Wang, S.; He, Y.; Wang, W.; Li, Q.; Cao, X. Ferulic acid inhibits advanced glycation end products (AGEs) formation and mitigates the AGEs-induced inflammatory response in HUVEC cells. *J. Funct. Foods* 2018, 48, 19–26. [CrossRef]

95. Ou, J.; Huang, J.; Wang, M.; Ou, S. Effect of rosmarinic acid and carnosic acid on AGEs formation in vitro. *Food Chem. 2017*, 221, 1057–1061. [CrossRef]

96. Shamsi, A.; Ahmed, A.; Khan, M.S.; Husain, F.M.; Bano, B. Rosmarinic acid restrains protein glycation and aggregation in human serum albumin: Multi spectroscopic and microscopic insight-possible therapeutics targeting diseases. *Int. J. Biol. Macromol.* 2020, 161, 187–193. [CrossRef]

97. Kim, J.; Jeong, I.-H.; Kim, C.-S.; Lee, Y.M.; Kim, J.M.; Kim, J.S. Chlorogenic acid inhibits the formation of advanced glycation end products and associated protein cross-linking. *Arch. Pharm. Res.* 2011, 34, 495–500. [CrossRef]

98. Chen, X.; Sang, X.; Li, S.; Zhang, S.; Bai, L. Studies on a chlorogenic acid-producing endophytic fungi isolated from *Eucommia ulmoides* Oliver. *J. Ind. Microbiol. Biotechnol.* 2010, 37, 447–454. [CrossRef] [PubMed]

99. Bibi, N.; Jan, G.; Jan, F.G.; Hamayun, M.; Iqbal, A.; Hussain, A.; Rehman, H.; Tawab, A.; Khushdil, F. *Cochliobolus* sp. acts as a biochemical modulator to alleviate salinity stress in okra plants. *Plant Physiol. Biochem.* 2019, 139, 459–469. [CrossRef] [PubMed]

100. Jang, D.S.; Lee, Y.M.; Jeong, I.H.; Kim, J.S. Constituents of the flowers of *Plantycodon grandiflorum* with inhibitory activity on advanced glycation end products and rat lens aldose reductase in vitro. *Arch. Pharm. Res.* 2010, 33, 875–880. [CrossRef]

101. Choi, J.S.; Islam, M.N.; Ali, M.Y.; Kim, E.J.; Kim, Y.M.; Jung, H.A. Effects of C-glycosylation on anti-diabetic, anti-Alzheimer’s disease and anti-inflammatory potential of apigenin. *Food Chem. Toxicol.* 2014, 64, 27–33. [CrossRef]

102. Zhou, Q.; Cheng, K.-W.; Gong, J.; Li, E.T.S.; Wang, M. Apigenin and its methylglyoxal-adduct inhibit advanced glycation end products-induced oxidative stress and inflammation in endothelial cells. *Biochem. Pharmacol.* 2019, 166, 231–241. [CrossRef]

103. Gu, C.B.; Ma, H.; Ning, W.J.; Niu, L.L.; Han, H.Y.; Yuan, X.H.; Fu, Y.J. Characterization, culture medium optimization and antioxidiant activity of an endophytic vitexin-producing fungus *Dickhotomopsis fusicola* Y3 from pigeon pea (*Cajanus cajan* (L.) Millsp.). *J. Appl. Microbiol.* 2018, 125, 1054–1065. [CrossRef] [PubMed]

104. Tang, P.; Zhang, Z.; Niu, L.; Gu, C.; Zheng, W.; Cui, H.; Yuan, X. *Fusarium solani* G6, a novel vitexin-producing endophytic fungus: Characterization, yield improvement and osteoblastic proliferation activity. *Biotechnol. Lett.* 2021, 43, 1371–1383. [CrossRef]
105. Gao, Y.; Zhao, J.; Zu, Y.; Fu, Y.; Liang, L.; Luo, M.; Wang, W.; Efferth, T. Antioxidant properties, superoxide dismutase and glutathione reductase activities in HepG2 cells with a fungal endophyte producing apigenin from pigeon pea [Cajanus cajan (L.) Millsp.]. *Food Res. Int.* 2012, 49, 147–152. [CrossRef]

106. Kim, J.M.; Lee, E.K.; Kim, D.H.; Yu, B.P.; Chung, H.Y. Kaempferol modulates pro-inflammatory NF-KB activation by suppressing advanced glycation endproducts-induced NADPH oxidase. *AGE* 2010, 32, 197–208. [CrossRef]

107. Al-Musayeb, N.; Perveen, S.; Fatima, I.; Nasir, M.; Hussain, A. Antioxidant, anti-glycation and anti-inflammatory activities of phenolic constituents from *Cordia sinensis*. *Molecules* 2011, 16, 10214–10226. [CrossRef]

108. Veeresham, C.; Rama Rao, A.; Asres, K. Aldose reductase inhibitors of plant origin: Aldose reductase inhibitors. *Phytother. Res.* 2014, 28, 317–333. [CrossRef] [PubMed]

109. Suchal, K.; Malik, S.; Khan, S.; Malhotra, R.; Goyal, S.; Bhatia, J.; Ohja, S.; Arya, D. Molecular pathways involved in the amelioration of myocardial injury in diabetic rats by kaempferol. *Int. J. Mol. Sci.* 2017, 18, 1001. [CrossRef] [PubMed]

110. Huang, J.-X.; Zhang, J.; Zhang, X.-R.; Zhang, K.; Zhang, X.; He, X.-R. *Muco rubra* as a novel source of the key pharmaceutical agents podophyllotoxin and kaempferol. *Pharm. Biol.* 2014, 52, 1237–1243. [CrossRef] [PubMed]

111. Tijith, K.G.; Joy, A.; Divya, K.; Jisha, M.S. In vitro and in silico docking studies of antibacterial compounds derived from endophytic *Penicillium setosum*. *Microb. Pathog.* 2019, 131, 87–97. [CrossRef]

112. Grzegorczyk-Karolak, I.; Goł ˛ ab, K.; Gburek, J.; Wysoki ´ nska, H.; Matkowski, A. Inhibition of advanced glycation end-product formation and antioxidant activity by extracts and polyphenols from *Scutellaria alpina* L. and *S. altissima* L. *Molecules* 2016, 21, 739. [CrossRef]

113. Ebada, S.S.; Eze, P.; Okoye, F.B.C.; Esimone, C.O.; Proksch, P. The fungal endophyte *Nigrospora oryzae* produces quercetin monoglycosides previously known only from plants. *ChemistrySelect* 2016, 1, 2767–2771. [CrossRef]

114. Cervantes-Laureen, D.; Schramm, D.D.; Jacobson, E.L.; Halaweish, I.; Bruckner, G.G.; Boissoneault, G.A. Inhibition of advanced glycation endproduct formation on collagen by rutin and its metabolites. *J. Nutr. Biochem.* 2006, 17, 531–540. [CrossRef]

115. Li, X.; Zheng, T.; Sang, S.; Lv, L. Quercetin inhibits advanced glycation end product formation by trapping methylglyoxal and glyoxal. *J. Agric. Food Chem.* 2014, 62, 12152–12158. [CrossRef]

116. Wu, Q.; Li, S.; Li, X.; Fu, X.; Sui, Y.; Guo, T.; Xie, B.; Sun, Z. A significant inhibitory effect on advanced glycation end product formation by catechin as the major metabolite of *Lotus seedpod* oligomeric procyanidins. *Nutrients* 2014, 6, 3230–3244. [CrossRef]

117. Shao, X.; Chen, H.; Zhu, Y.; Sedighi, R.; Ho, C.-T.; Sang, S. Essential structural requirements and additive effects for flavonoids to scavenge methylglyoxal. *J. Agric. Food Chem.* 2012, 60, 3202–3210. [CrossRef]

118. Hsieh, P.-W.; Hsu, L.-C.; Lai, C.-H.; Wu, C.-C.; Hwang, T.-L.; Lin, Y.-K.; Wu, Y.-C. The fungal endophyte *Alternaria* sp. MG1, a resveratrol producing fungus: Isolation, identification, and optimal production. *Appl. Biochem. Biotechnol.* 2018, 205, 152917. [CrossRef] [PubMed]

119. Chen, H.; Chen, C.-M.; Guan, S.-S.; Chiang, C.-K.; Wu, C.-C.; Hwang, T.-L.; Lin, Y.-K.; Wu, Y.-C. Evaluation of the bioactivities of extracts of endophytes isolated from Taiwanese herbal plants. *World J. Microbiol. Biotechnol.* 2009, 25, 1461–1469. [CrossRef]

120. Li, X.; Wang, Y.; Shi, P.; Liu, Y.; Li, T.; Liu, S.; Wang, C.; Wang, L.; Cao, Y. Icariin treatment reduces blood glucose levels in type 2 diabetic rats and protects pancreatic function. *Exp. Ther. Med.* 2020, 19, 2690–2696. [CrossRef] [PubMed]

121. Ghorbani, A. Mechanisms of antiabetic effects of flavonoid rutin. *Biomed. Pharmacother.* 2017, 96, 305–312. [CrossRef] [PubMed]

122. Palsamy, P.; Subramanian, S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2–Keap1 signaling. *Biochim. Biophys. Acta BBA-Mol. Basis Dis.* 2011, 1812, 719–731. [CrossRef]

123. Shen, Y.; Xu, Z.; Sheng, Z. Ability of resveratrol to inhibit advanced glycation end product formation and carbohydrate-hydrolyzing enzyme activity, and to conjugate methylglyoxal. *Food Chem.* 2017, 216, 153–160. [CrossRef]

124. Shi, J.; Zeng, Q.; Liu, Y.; Pan, Z. *Alternaria* sp. MG1, a resveratrol-producing fungus: Isolation, identification, and optimal cultivation conditions for resveratrol production. *Appl. Microbiol. Biotechnol.* 2012, 95, 369–379. [CrossRef]

125. Dwibedi, V.; Saxena, S. Arctopilus aureus, a resveratrol-producing endophyte from *Vitis vinifera*. *Appl. Biochem. Biotechnol.* 2018, 186, 476–495. [CrossRef]

126. Dwibedi, V.; Saxena, S. Diversity and phylogeny of resveratrol-producing culturable endophytic fungi from *Vitis* species in India. *3 Biotech* 2019, 9, 182. [CrossRef]

127. Dwibedi, V.; Saxena, S. Effect of precursor feeding, dietary supplementation, chemical elicitors and co-culturing on resveratrol production by *Arctopilus aureus*. *Prep. Biochem. Biotechnol.* 2022, 52, 404–412. [CrossRef]

128. Liu, Y.; Nan, L.; Liu, J.; Yan, H.; Zhang, D.; Han, X. Isolation and identification of resveratrol-producing endophytes from wine grape Cabernet Sauvignon. *SpringerPlus* 2016, 5, 1029. [CrossRef] [PubMed]

129. Chandramohan, R.; Pari, L.; Rathinam, A.; Sheikh, B.A. Tyrosol, a phenolic compound, ameliorates hyperglycemia by regulating key enzymes of carbohydrate metabolism in streptozotocin induced diabetic rats. *Chem. Biol. Interact.* 2015, 229, 44–54. [CrossRef] [PubMed]

130. Kwon, Y.-I.; Jang, H.-D.; Shetty, K. Evaluation of *Rhodiola crenulata* and *Rhodiola rosea* for management of type II diabetes and hypertension. *Asia Pac. J. Clin. Nutr.* 2006, 15, 425–432. [PubMed]

131. McMullin, D.R.; Green, B.D.; Prince, N.C.; Tanney, J.B.; Miller, J.D. Natural products of *Picea* endophytes from the Acadian Forest. *J. Nat. Prod.* 2017, 80, 1475–1483. [CrossRef] [PubMed]
158. Anwar, S.; Khan, S.; Almatroudi, A.; Khan, A.A.; Alsahli, M.A.; Almatroodi, S.A.; Rahmani, A.H. A review on mechanism of inhibition of advanced glycation end products formation by plant derived polyphenolic compounds. *Mol. Biol. Rep.* 2021, 48, 787–805. [CrossRef] [PubMed]

159. Chen, Y.; Hu, B.; Xing, J.; Li, C. Endophytes: The novel sources for plant terpenoid biosynthesis. *Appl. Microbiol. Biotechnol.* 2021, 105, 4501–4513. [CrossRef] [PubMed]

160. Ludwig-Müller, J. Plants and endophytes: Equal partners in secondary metabolite production? *Biotechnol. Lett.* 2015, 37, 1325–1334. [CrossRef] [PubMed]

161. Pandey, S.S.; Singh, S.; Babu, C.S.V.; Shanker, K.; Srivastava, N.K.; Kalra, A. Endophytes of *Opium poppy* differentially modulate host plant productivity and genes for the biosynthetic pathway of benzylisoquinoline alkaloids. *Planta* 2016, 243, 1097–1114. [CrossRef]

162. Lin, L.-C.; Lin, C.-Y.; Lin, W.-R.; Tung, Y.-T.; Wu, J.-H. Effects of ericoid mycorrhizal fungi or dark septate endophytic fungi on the secondary metabolite of *Rhododendron pseudochrysanthum* (*R. morii*) seedlings. *Appl. Ecol. Environ. Res.* 2021, 19, 1221–1232. [CrossRef]

163. Zych, M.; Wojnar, W.; Kielanowska, M.; Folwarczna, J.; Kaczmarczyk-Sedlak, I. Effect of berberine on glycation, aldose reductase activity, and oxidative stress in the lenses of streptozotocin-induced diabetic rats in vivo—a preliminary study. *Int. J. Mol. Sci.* 2020, 21, 4278. [CrossRef]

164. Liu, T.; Zhang, X.; Tian, S.; Chen, L.; Yuan, J. Bioinformatics analysis of endophytic bacteria related to berberine in the Chinese medicinal plant *Coptis teeta* Wall. *3 Biotech* 2020, 10, 96. [CrossRef]

165. Zimowska, B.; Bielecka, M.; Abramczyk, B.; Nicoletti, R. Bioactive products from endophytic fungi of sages (*Salvia* spp.). *Agriculture* 2020, 10, 543. [CrossRef]

166. Bier, M.C.J.; Medeiros, A.B.P.; Soccol, C.R. Biotransformation of limonene by an endophytic fungus using synthetic and orange residue-based media. *Fungal Biol.* 2017, 121, 137–144. [CrossRef]

167. Tian, Y.; Amand, S.; Buisson, D.; Kunz, C.; Hachette, F.; Dupont, J.; Nay, B.; Prado, S. The fungal leaf endophyte *Paraconiothyrium variable* specifically metabolizes the host-plant metabolome for its own benefit. *Phytochemistry* 2014, 108, 95–101. [CrossRef]

168. Harwoko, H.; Hartmann, R.; Daletos, G.; Ancheeva, E.; Frank, M.; Liu, Z.; Proksch, P. Biotransformation of host plant flavonoids by the fungal endophyte *Epicoccum nigrum*. *ChemistrySelect* 2019, 4, 13054–13057. [CrossRef]

169. Kusari, S.; Hertweck, C.; Spiteller, M. Chemical ecology of endophytic fungi: Origins of secondary metabolites. *Chem. Biol.* 2012, 19, 792–798. [CrossRef] [PubMed]

170. Xu, F.; Wang, S.; Li, Y.; Zheng, M.; Xi, X.; Cao, H.; Cui, X.; Guo, H.; Han, C. Yield enhancement strategies of rare pharmaceutical metabolites from endophytes. *Biotechnol. Lett.* 2018, 40, 797–807. [CrossRef] [PubMed]